Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Satisfaction with Paliperidone ER Switch in Schizophrenia
NCT01592201Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paliperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Medication Satisfaction Questionnaire at 8 weeks. Started Jul 2012; status: terminated.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01592201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592201.